Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06454968
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-05-27
Brief Title:
Orelabrutinib Combined With Obinutuzumab and Lenalidomide OGL Regimen as First-line Treatment for Marginal Zone Lymphoma
Sponsor:
Organization:
Peking Union Medical College Hospital